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Interleukin-17 (IL-17) secreted by T helper 17 (Th17)
cells is essential in the development of experimental
autoimmune encephalomyelitis (EAE). However, it
remains unclear how IL-17-mediated signaling in
different cellular compartments participates in the
central nervous system (CNS) inflammatory process.
We examined CNS inflammation inmicewith specific
deletion of Act1, a critical component required for
IL-17 signaling, in endothelial cells, macrophages
and microglia, and neuroectoderm (neurons, astro-
cytes, and oligodendrocytes). In Act1-deficient
mice, Th17 cells showed normal infiltration into the
CNS but failed to recruit lymphocytes, neutrophils,
and macrophages. Act1 deficiency in endothelial
cells or in macrophages and microglia did not sub-
stantially impact the development of EAE. However,
targeted Act1 deficiency in neuroectoderm-derived
CNS-resident cells resulted in markedly reduced
severity in EAE. Specifically, Act1-deficient astro-
cytes showed impaired IL-17-mediated inflamma-
tory gene induction. Thus, astroctyes are critical in
IL-17-Act1-mediated leukocyte recruitment during
autoimmune-induced inflammation of the CNS.
INTRODUCTION
Multiple sclerosis (MS) is an autoimmune disease in which T
lymphocytes reactive to myelin antigens initiate an inflammatory
response in the central nervous system (CNS) leading to demy-
elination and subsequent axonal injury (Becher et al., 2006; Gold
et al., 2006; Sospedra and Martin, 2005). Experimental autoim-
mune encephalomyelitis (EAE) is an animal model commonly
used to study the immunopathogenesis of multiple sclerosis
(Stromnes andGoverman, 2006). EAE is induced by either immu-
nization of animals with myelin antigens or the adoptive transfer
of myelin antigen-specific T cells. EAE can be subdivided into an
initiation stage involving activation and expansion of myelin-414 Immunity 32, 414–425, March 26, 2010 ª2010 Elsevier Inc.specific T cells in the periphery, which then cross the blood brain
barrier (BBB), an effector stage involving reactivation of myelin-
specific T cells in the CNS, resulting in cytokine-induced chemo-
kine expression in CNS-resident cells, therebymediating recruit-
ment of hematogenously derived inflammatory cells, and a stage
of remission and repair in which the immune response is down-
regulated (McFarland and Martin, 2007; Steinman, 2001).
Whereas T helper 1 (Th1) cells were shown to play a critical role
in the initiation of inflammatory responses in CNS (Agrawal et al.,
2006; Bettelli et al., 2004; Korn et al., 2009; Yang et al., 2009),
Th2 cells were considered as counterinflammatory (Butti et al.,
2008; Kleinschek et al., 2007; Ramı´rez and Mason, 2000). This
Th1-Th2 cell paradigm was challenged by the fact that lack of
interferon-g (IFN-g) leads to increased EAE phenotype (Cua
et al., 2003; Ferber et al., 1996). Importantly, both Th1 and
Th17 cells can independently induce EAE possibly through
different mechanisms (Lees et al., 2008; Kroenke et al., 2008;
Stromnes et al., 2008; Park et al., 2005), and even Th2 cells
can lead to a mild atypical form of EAE (Das et al., 1997; Ja¨ger
et al., 2009; Steinman, 2008). Th17 cells are generated as
a discrete lineage after priming in the presence of the cytokines
TGF-b and IL-6 and acquisition of encephalitogenicity after
proliferation in the presence of IL-23 (Cua et al., 2003; Mangan
et al., 2006; Veldhoen et al., 2006). Th17 cells are now recog-
nized at least as one of the major mediators of tissue damage
in EAE (Haak et al., 2009; Yang et al., 2009; Steinman, 2009).
EAE is markedly suppressed in mice lacking IL-17 or IL-17
receptor, and IL-17-specific inhibition attenuates inflammation
indicating that IL-17-mediated signaling plays a critical role in
the effector stage of EAE (Gonzalez-Garcı´a et al., 2009; Ko-
miyama et al., 2006; Park et al., 2005; Harrington et al., 2005;
Veldhoen et al., 2006). However, the precise mechanism by
which IL-17 participates in EAE development and pathogenesis
remains unclear.
A major function of IL-17 involves coordination of local tissue
inflammation through upregulation of proinflammatory and
neutrophil-mobilizing cytokines and chemokines including IL-6,
G-CSF, TNF-a, IL-1, CXCL1(KC), CCL2(MCP-1), CXCL2(MIP-2),
CCL7(MCP-3), andCCL20(MIP-3A) aswell asmatrix metallopro-
teases (MMPs) to allow activated T cells to penetrate the extra-
cellular matrix (Awane et al., 1999; Weaver et al., 2005; Jova-
novic et al., 1998). Several new studies have shown that IL-17
Figure 1. Act1 Deficiency Impairs Inflam-
matory Cell Infiltration in the CNS
(A and B) Immune cell infiltration in the brains of
MOG 35-55-immunized wild-type and Act1/
mice (n = 7, 7 days after disease onset) was
analyzed by flow cytometry. Error bars, SEM.
*p < 0.05.
(C) Luxol fast blue, hematoxylin and eosin, and
anti-CD11b and CD4 staining of spinal cords of
wild-type and Act1-deficient mice at peak of
disease. Data are representative of three inde-
pendent experiments. See also Figure S1.
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Act1 in Central Nervous System Is Critical for EAEsignals through a heteromeric receptor complex, consisting of
IL-17R (IL-17RA) and IL-17RC, which are single-pass transmem-
brane proteins expressed by a variety of cells including astro-
cytes and microglia (Inoue et al., 2006; Kolls and Linde´n, 2004;
Toy et al., 2006; Trajkovic et al., 2001). The important questions
are whether and how these CNS-resident cells respond to IL-17
to mediate inflammatory response in the central nervous system
leading to demyelination and subsequent axonal injury.
Both IL-17RA and IL-17RC belong to a newly defined SEFIR
protein family with a conserved sequence segment called SEFIR
in their cytoplasmic domain (Novatchkova et al., 2003). We
recently described the signaling molecule Act1 as a key compo-
nent in IL-17 signaling (Qian et al., 2007). Act1 contains two TRAF
binding sites: a helix-loop-helix domain at the N terminus and
a coiled-coil domain at the C terminus (Li et al., 2000; Qian
et al., 2002; Leonardi et al., 2000). Act1 contains a SEFIR domain
in its coiled-coil region at the C terminus and therefore Act1 isImmunity 32, 414–425a member of the SEFIR protein family
(Novatchkova et al., 2003). Upon IL-17
stimulation, Act1 is recruited to IL-17R
through the IL-17R conserved cyto-
plasmic SEFIR domain, which is followed
by recruitment of the kinase TAK1 and E3
ubiquitin ligase TRAF6 that mediate
‘‘downstream’’ NF-kB activation. Act1
deficiency results in reduced EAE
severity in the presence of normal activa-
tion and expansion of encephalitogenic
Th17 T cells, indicating that IL-17-
induced Act1-mediated signaling plays
a critical role in the effector stage of
EAE development. However, it remains
unclear how IL-17-mediated signaling in
different cellular compartments partici-
pates in CNS inflammation during EAE.
In the current study, we aimed to define
the specific cell types that are critical
for IL-17-dependent autoimmune inflam-
mation of the CNS. By cell type-specific
deletion of Act1, we showed that Act1
deficiency in the CNS-resident cells orig-
inated from neuroectodermal cells
(neurons, astrocytes, and oligodendro-
cytes) delayed the onset and reduced
the severity of EAE induced by eitheractive immunization with the encephalitogenic MOG 35-55
peptide or by adoptive transfer of MOG-specific Th17 T cells.
RESULTS
Act1 Is Required for the Effector Stage of Th17 Cell- but
Not Th1 Cell-Induced EAE
Our previous studies have shown that the onset and severity of
EAE are greatly reduced in mice lacking Act1, the key adaptor
molecule of IL-17R (Figure S1 available online). Act1-deficient
(Act1/) mice had fewer CNS inflammatory cells, including
neutrophils, macrophages, CD4+, and CD8+ T cells compared
to wild-type control mice (Figures 1A and 1B). Furthermore,
histological examination revealed abundant CD4+ T cells and
CD11b+ leukocytes in the meninges and in the spinal cord
parenchyma, accompanied by severe demyelination in the
white matter in wild-type mice (Figure 1C). In contrast,, March 26, 2010 ª2010 Elsevier Inc. 415
Figure 2. Act1 Is Required for the Effector Stage of Th17 Cell- but Not Th1 Cell-Induced EAE
(A) Draining lymph node cells from wild-type mice and Act1/ mice 10 days after immunization with MOG35-55 were restimulated with MOG35-55 in vitro for
4 days, followed by ELISA of IL-17, IFN-g. Error bars, SEM; n = 5 mice per group. *p < 0.05.
(B–D) Primed MOG 35-55-specific T cells (10 days) from (B) wild-type or (C) Act1/mice were restimulated with MOG 35-55 in vitro in the presence of recombi-
nant IL-23 for 5 days and then transferred to naive wild-type or Act1/ mice. Graph represents the average clinical score after T cell transfer.
(D) Primed MOG 35-55-specific wild-type T cells (10 days) were restimulated with MOG 35-55 in vitro in the presence of recombinant IL-12 and anti-IL-23p19 for
5 days and then transferred to naive wild-type and Act1/ mice. Graph represents the average clinical score after T cell transfer.
(E) H&E staining of the spinal cords of wild-type and Act1/ mice transferred with Th1 and Th17 cells and sacrificed 7 days after the onset of disease.
(F) Immune cell infiltration in the brains of wild-type and Act1/mice transferred with wild-type Th1 cells (n = 5, 7 days after disease onset) was analyzed by flow
cytometry.
Error bars, SEM. Data are representative of three independent experiments. See also Figure S2.
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Act1 in Central Nervous System Is Critical for EAEinflammatory cells were reduced in spinal cords from Act1/
mice coincident with minimum signs of demyelination
(Figure 1C). The absence of Act1 therefore leads to impaired
CNS inflammation, resulting in reduced demyelination and
subsequent axonal injury.
Supernatants from primed lymph node cells of Act1/ mice
showed increased production of Th1 (IFN-g) and Th17 (IL-17)
cell-associated cytokines relative to primed wild-type mice
(Figure 2A). Consistent with this finding, intracellular staining
showed increased numbers of IFN-g- and IL-17-producing
CD4+ T cells in the primed lymph node cells of Act1/ mice
than that in wild-type mice. IL-17-producing gd T cells were
also increased in the primed lymph node cells of Act1/ mice
compared to that in wild-type mice (Figure S2A). The impact of
Act1 deficiency on IFN-g- and IL-17-producing CD4+ and gd
T cells in peripherymight be related to the hyper T cell-dependent
immune responses previously observed in the Act1/ mice
(Qian et al., 2007), although the detailed mechanism remains
unclear. Importantly, activated MOG 35-55-specific Th1 (Qian
et al., 2007) and Th17 cells derived from primed Act1/ mice
were both fully encephalitogenic because they were able to
passively transfer EAE in wild-type recipients (Figures 2B–2D;416 Immunity 32, 414–425, March 26, 2010 ª2010 Elsevier Inc.Figures S2B and S2C). Thus, Act1/ mice had no defect in the
activation of MOG 35-55-specific Th17 or Th1 cells.
Both wild-type and Act1/ MOG 35-55-specific Th17 cells
induced EAE in wild-type recipients. However, the onset and
severity of EAE were greatly reduced in Act1/ recipients, inde-
pendent of the genotype of the transfer population (Figures 2B
and 2C). These results demonstrate that Act1 is required for
the effector stage of EAE induced by Th17 cells. However, recent
studies and the results described above indicate that Th1 cells
can also induce EAE. To show that Act1 only acts through
Th17 cells and not Th1 cells, the activated MOG-specific Th1
cells polarized from wild-type mice were tested for EAE induc-
tion. Act1/-recipient mice of Th1 cells exhibited similar onset
and severity of EAE as wild-type recipients, indicating that
Act1 deficiency has no obvious impact on the effector stage of
Th1 cell-induced EAE (Figures 2D–2F).
Th17 Cells Infiltrate the CNS but Fail to Initiate
a Pathogenic Inflammatory Cascade in Act1/ Mice
Our results clearly indicate that Act1 deficiency does not impair
peripheral activation of MOG 35-55-specific T cells, but rather
affects functions within the CNS. Furthermore, Th17 cell
Immunity
Act1 in Central Nervous System Is Critical for EAEresponses in the CNS are associated with recruitment of bone
marrow-derived myeloid cells (Park et al., 2005; Komiyama
et al., 2006; Harrington et al., 2005; Mangan et al., 2006; Kolls
and Linde´n, 2004; Veldhoen et al., 2006). We therefore investi-
gated a role of Act1 in CNS recruitment of MOG-specific
T cells as well as subsequent recruitment of other mononuclear
cells. MOG-specific T cells were isolated from the lymph nodes
of Thy1.1 C57BL/6 mice 10 days after MOG 35-55 immunization,
polarized to Th17 cells, and transferred into Thy1.2+ wild-type or
Act1/ mice. Similar numbers of Thy1.1+CD4+ donor T cells
were detected in the brains of wild-type and Act1/ brains at
days 3 and 5, early after adoptive transfer. However, during the
later phase at days 12 and 15, at the peak of the disease, signif-
icantly more Thy1.1+CD4+ T cells and monocytes accumulated
in the brains of wild-type compared to Act1/ mice (Figures
3A–3C). Overall, the vast majority of CNS-derived CD4+ T cells
were of donor Thy1.1 phenotype throughout disease induction
(data not shown). We also examined the Thy1.1+CD4+ T cells
in the spleen of wild-type and Act1/ recipient mice after
adoptive transfer. We detected more Thy1.1+CD4+ T cells in
the spleen of the Act1/ mice at day 5 and day 12 compared
to that in wild-type control mice. By day 15, Thy1.1+CD4+
T cells disappeared from spleen. The temporal retention of
Thy1.1+CD4+ T cells in the Act1/ spleen might reflect the
reduced recruitment of these cells to the Act1/ CNS
(Figure 3D).
These results indicate that Th17 cells can infiltrate the CNS of
Act1/ mice but fail to initiate an effective inflammatory
response, presumably because of the inability to propagate
IL-17-mediated signaling. IL-17-induced signature cytokines
and chemokines were indeed markedly reduced in the spinal
cord of the Act1/ recipient mice at the peak of disease after
adoptive transfer of MOG-specific Thy1.1+ Th17 cells
(Figure 3E). Of note, both CXCL1 and MMP9 associated with
neutrophil recruitment, as well as IL-6 and CXCL12 involved in
parenchymal leukocyte access, were reduced in Act1/ recip-
ients. As a result, the inflammatory amplification loop is blocked,
leading to reduced recruitment of inflammatory cells.
It is important to note that in addition to Thy1.1+CD4+ IL-17-
producing cells in the brain of the recipient mice at the peak of
the disease, IL-17-producing Thy1.1+gd T cells were also de-
tected in the brain of these mice (Figures 3F and 3G). Consistent
with the clinical signs of the mice (Figure 3A), the absolute
numbers of IFN-g- and IL-17-producing Thy1.1+CD4+ T cells
and Thy1.1+gd T cells were significantly reduced at the peak of
the disease in the brain of Act1/-recipient mice compared to
that in the wild-type control mice. IL-17-producing CD4+ (Th17)
cells activated in the presence of IL-23 in the primary culture
(Figure S2C) were relatively stable in vivo (Figures 3F and 3G),
whereas the IL-17-producing Thy1.1+gd T cells showed more
plasticity in vivo, becoming IFN-g and IL-17 double-positive cells
or IFN-g-producing cells (Figures 3F and 3G). In contrast, the
majority of both CD4+ T cells and gd T cells activated in the pres-
ence of IL-12 in the primary culture (Figure S2B) remain as IFN-g-
producing cells in the brain of the recipient mice, indicating their
stability in vivo (Figure S2D). This result is consistent with the fact
that Act1 deficiency did not show any impact on Th1 cell-medi-
ated EAE, because these ‘‘Th1’’ cells remain as IFN-g-producing
cells in the brain after adoptive transfer (Figure S2D).Act1 Deficiency in Recipient Mice Does Not Impact
Proliferation or Survival of CNS Th17 Cells
We further investigated whether the reduced IL-17-induced
cytokine and chemokine production in the CNS has any impact
on CD4+ T cell survival and/or proliferation. To test this possi-
bility, MOG 35-55-specific Thy1.1+ Th17 cells were adoptively
transferred into Thy1.2 Act1/ and wild-type recipient mice.
Thy1.1+ cells costained with Ki-67, indicating that the infiltrated
Thy1.1+ cells were in a proliferating state irrespective of their
wild-type or Act1/ environment in recipients (Figure 4A).
Furthermore, the frequency of infiltrated CD4+Brdu+ cells in the
spinal cord of wild-type mice was similar to that in Act1/
mice (Figure 4B). Thus, the reduced accumulation of Thy1.1+
cells in the CNS of Act1/ mice at the peak of disease cannot
be attributed to their reduced proliferation or survival, but rather
reflects impaired chemokine- and/or cytokine-mediated recruit-
ment of activatedmyeloid cells, which in turn propagate ongoing
inflammation.
Endothelial-Derived Act1 Is Dispensable for EAE
Development
Laminin is present in both endothelial basement membrane and
parenchymal basement membrane (Bauer et al., 2009; Sixt et al.,
2001) providing a tool to visualize inflammatory cells in the peri-
vascular space. No differences were noted in the distribution of
MOG 35-55-specific Thy1.1+ Th17 cells in wild-type compared
to Act1-deficient recipient mice (Figure 5A). Although some
Thy1.1 cells were in close proximity to laminin, a large proportion
had spread into the parenchyma. These results negated a role for
Act1 in influencing access of myelin-specific T cells through the
BBB into the CNS parenchyma. Nevertheless, previous studies
have shown that the IL-17 receptor is expressed on BBB endo-
thelial cells (Kebir et al., 2007), potentially influencing induction of
chemokines or cytokines. To further explore whether endothelial
cell-specific IL-17-induced Act1-mediated signaling impacts
EAE pathogenesis, we generated endothelial cell-specific
Act1-deficient mice. TIE2eCre transgenic mice (generated with
the endothelial-specific TIE2e promoter) express Cre within
endothelium of brain, heart, and liver, among others. Real-time
PCR showed that Act1 expression was indeed abolished in
PECAM-1+ endothelial cells from the TIE2eCreAct1fl/ mice
(Figure 5B). The onset and disease severity of EAE were similar
in TIE2eCreAct1fl/ and TIE2eCreAct1fl/+ mice after either
immunization with MOG 35-55 or adoptive transfer with MOG
35-55-specific Th17 cells (Figures 5C and 5D). However, EAE
induced by active immunization resulted in fewer CD4+ and
CD8+ T cells in the CNS of the endothelial-specific Act1-deficient
mice compared to control mice during the recovery phase of
disease (Figure 5E). Therefore, despite moderate effects of
endothelial-derived Act1 on the leukocyte infiltration, they were
insufficient to have a substantial impact on clinical symptoms
of Th17 cell-mediated EAE.
Macrophage- and Microglial-Derived Act1 Are
Dispensable for EAE Development
Perivascular macrophages and microglia are important antigen-
presenting cells in the CNS, which can also produce inflamma-
tory cytokines and chemokines upon activation (Aloisi, 2001;
Carson, 2002). Macrophages are one of the major effector cellsImmunity 32, 414–425, March 26, 2010 ª2010 Elsevier Inc. 417
Figure 3. Th17 Cells Can Infiltrate CNS but Fail to Initiate Effective Inflammatory Cascade in Act1/ Mice
(A) Mean clinical score of wild-type and Act1/ mice adoptively transferred with MOG-specific Thy1.1+ Th17 cells (n = 4/group). Lymph node cells harvested
from Thy1.1 C57BL/6 mice 10 days after immunization with MOG 35-55 were polarized to Th17 cells as described in Figure 2 and transferred to wild-type
and Act1/ mice. Graph represents the average clinical score after T cell transfer.
(B–D) Immune cell infiltration in the (B, C) brain and (D) spleen of wild-type and Act1/mice transferred with MOG-specific Thy1.1+ Th17 cells (n = 5/group, 3, 5,
12, and 15 days after T cell transfer) was analyzed by flow cytometry. Error bars, SEM; *p < 0.05.
(E) Real-time PCR analysis of relative expression of inflammatory genes as indicated in spinal cords of wild-type and Act1/mice transferred with MOG-specific
Thy1.1+ Th17 cells (n = 3, 15 days after T cell transfer) compared to the control samples from naive mice.
(F andG) Intracellular staining for the infiltrated IL-17-secreting or IFN-g-secreting Thy1.1+CD4+ T cells and Thy1.1+ gd T cells in the brain of wild-type andAct1/
mice transferred with MOG-specific Thy1.1+ Th17 cells (n = 10/group, 15 days after T cell transfer). The frequency of IL-17+ or IFN-g+ cells in Thy1.1+CD4+ cell
population (top) and Thy1.1+ gd T cells (bottom) were shown in (F) and the corresponding absolute cell numbers were shown in (G).
See also Figure S2.
Immunity
Act1 in Central Nervous System Is Critical for EAEin CNS damage during EAE development. Because IL-17
responsiveness has been detected in both microglia andmacro-
phages, it is critical to examine the importance of IL-17-induced418 Immunity 32, 414–425, March 26, 2010 ª2010 Elsevier Inc.Act1-mediated signaling in macrophages and microglial cells for
the pathogenesis of EAE. CD11bCre transgenic mice (generated
with the promoter for CD11b, an integrin expressed exclusively
Figure 4. Act1 Deficiency in the Recipient Mice Does
Not Impact on the Proliferation and Survival of the
Infiltrated Th17 Cells
(A) Immunofluorescent staining for Ki67-positive Thy1.1 cells
in the spinal cords of wild-type and Act1-deficient mice trans-
ferred with MOG-specific Thy1.1+ Th17 cells (n = 4, 12 days
after T cell transfer). Frozen sections of spinal cords collected
from the recipient mice were stained with Thy1.1 (red) and
Ki67 (green) antibodies. The presented frequency of Ki67+
cells in total Thy1.1+ cells in the spinal cord was an average
of four spinal cord regions each group. Error bars, SEM.
(B) Brdu incorporation of infiltrated T cells in the spinal cords
of wild-type and Act1/mice transferred with MOG-specific
Thy1.1+ Th17 cells (n = 4, 12 days after T cell transfer). On day
12 after adoptive transfer of MOG-specific Thy1.1+ Th17
cells, wild-type and Act1/ recipient were administrated
with Brdu (i.p., 1 mg/mouse). Spinal cords were collected
from the recipient mice 12 hr after Brdu administration and
stained with Brdu antibody (red) and CD4 antibody (green).
The presented percentage of Brdu-positive cells in total
CD4+ cells was an average of four spinal cord regions each
group. Error bars, SEM.
Immunity
Act1 in Central Nervous System Is Critical for EAEin the myeloid lineage) express Cre in macrophages and micro-
glia. CD11bCreAct1+/ mice were bred onto Act1fl/fl to generate
control mice (CD11bCreAct1fl/+) and macrophage- and micro-
glia-specific Act1-deficient mice (CD11bCreAct1fl/). Real-time
PCR showed that Act1 expression was abolished in bone
marrow-derived macrophage and in microglia cultures derived
from CD11bCreAct1fl/ mice (Figure 6A). Immunoblots
confirmed the absence of Act1 expression in macrophages
and demonstrated a negligible contribution of microglia-derived
Act1 to overall protein expression in both brain and spinal cord
(Figure 6B). Both immunization with MOG 35-55 and adoptive
transfer of activated MOG 35-55-specific Th17 cells resulted
in similar onset and disease severity of EAE in the
CD11bCreAct1fl/ mice compared to control mice (Figures 6C
and 6D). Interestingly, infiltrating Ly6G+ neutrophils were
reduced in CNS of CD11bCreAct1fl/ mice compared to that in
control mice, whereas total numbers of F4/80+ microglia and
monocytes were not affected (Figure 6E). These results indicate
that macrophage- and microglial-specific Act1 deficiency has
some impact on the recruitment of polymorphonuclear neutro-
phils. Importantly, however, reduced neutrophils did not have
a substantial impact on clinical signs of Th17 cell-mediated
EAE pathogenesis.
Amelioration of EAE by Targeting Act1 in CNS-Resident
Cells Derived from Neuroectodermal Cells
The results above revealed that Act1 signaling in either endothe-
lial cells or myeloid cells is not the major source contributing to
Th17 cell-mediated EAE pathogenesis. We therefore investi-
gated the impact of other CNS-resident cells in Th17 cell-medi-
ated EAE development and pathogenesis. The NesCre trans-Immunity 32gene mediates excision of LoxP-flanked
sequences in early neuronal precursors during
embryonic life, resulting in efficient target gene
inactivation in all neuroectodermal cells of the
CNS, including neurons, astrocytes, and oligoden-
drocytes (Graus-Porta et al., 2001; Tronche et al.,1999). For CNS-restricted ablation of Act1, the Act1/ mice
were first bred onto NesCre transgenic mice to generate Ne-
sCreAct1+/ mice. These mice were further bred onto Act1fl/fl
mice to generate control mice (NesCreAct1fl/+) and CNS-
restricted Act1-deficient mice (NesCreAct1fl/). Immunoblot
analysis showed that Act1 expression was completely ablated
in astrocytes derived from NesCreAct1fl/ mice (Figure 7A).
Moreover, Act1 expression was also dramatically reduced in
the brains of the NesCreAct1fl/ mice (Figure 7A).
To determine the impact of CNS-restricted Act1 deficiency on
EAE development, EAEwas induced in NesCre Act1fl/mice and
control mice (NesCreAct1fl/+) by active immunization with MOG
33-55. The onset of EAE was significantly delayed in
NesCreAct1fl/ compared to that in control mice. Importantly,
NesCreAct1fl/ mice exhibited greatly reduced disease severity
(Figure 7B). Consistent with reduced clinical disease, mononu-
clear cell infiltrates were substantially decreased in white matter
of spinal cords from NesCreAct1fl/ relative to control mice
(Figure 7C). Control mice exhibited many CD4+ T cells and
CD11b+ leukocytes in themeninges and in the spinal cord paren-
chyma, accompanied by histological signs of severe demyelin-
ation in the white matter (Figure 7C). In contrast, reduced inflam-
matory cells in spinal cords from NesCreAct1fl/mice coincided
with minimum signs of demyelination (Figure 7C). Therefore, the
lack of Act1 in these CNS-resident cells leads to impaired infiltra-
tion of inflammatory cells into the CNS, resulting in reduced
demyelination.
Consistent with the fact that Act1 deficiency does not impair
the activation of MOG 35-55-specific T cells in EAE, superna-
tants from 10-day primed lymph node cells from both
NesCreAct1fl/ and NesCreAct1fl/+ control mice showed, 414–425, March 26, 2010 ª2010 Elsevier Inc. 419
Figure 5. Endothelial-Derived Act1 Is Dispensable for EAE Develop-
ment
(A) Immunofluorescent staining of CD4+ T cells relative to the vasculature in the
spinal cord. Spinal cords of wild-type and Act1/ mice transferred with
MOG-specific Thy1.1+ Th17 cells (n = 3, 12 days after T cell transfer) were
stained with CD4 (green) and pan-laminin (red) antibodies. The presented
data are a representative of three independent experiments.
(B) Real-time PCR for the Act1 expression in PECAM-1+ heart endothelial
cells from endothelial-specific Act1-deficient (TIE2eCreAct1fl/) and control
(TIE2eCreAct1fl/+) mice.
(C) Mean clinical score of EAE in TIE2eCreAct1fl/ and TIE2eCreAct1fl/+
induced by active immunization with MOG 35-55 (n = 5/group).
(D) Mean clinical score of EAE in TIE2eCreAct1fl/ and TIE2eCreAct1fl/+ mice
induced by MOG-specific wild-type Th17 cells.
(E) Flow cytometry analysis of immune cell infiltration in the brains of MOG
35-55 immunized TIE2eCreAct1fl/ and TIE2eCreAct1fl/+ mice (n = 5, 14 days
after disease onset).
Error bars, SEM; *p < 0.05.
Immunity
Act1 in Central Nervous System Is Critical for EAEcomparable frequency of Th1 and Th17 cells (Figure S3). To
confirm that the resistance of NesCreAct1fl/ mice to EAE is
due to the the effector stage of EAE, both NesCreAct1fl/+ and
NesCreAct1fl/ mice were used as recipients of activated wild-
type MOG 35-55-specific Th1 or Th17 cells. Whereas the Th1420 Immunity 32, 414–425, March 26, 2010 ª2010 Elsevier Inc.cells induced a similar EAE phenotype in both groups of mice,
the onset and severity of Th17 cell-induced EAE were greatly
reduced in NesCreAct1fl/ compared to that in control mice
(Figures 7D and 7E). The NesCreAct1fl/ mice had fewer inflam-
matory cells, including CD4+ and CD8+ T cells, macrophages,
and neutrophils, infiltrating the CNS at peak of disease than
did control mice after Th17 cell transfer (Figure 7E).
Impaired IL-17-Mediated Inflammatory Gene Induction
in Astrocytes from CNS-Restricted Act1-Deficient Mice
During EAE, signature IL-17-responsive inflammatory genes
(cytokines, chemokines, and matrix metalloproteinases) are
significantly induced in CNS (Weaver et al., 2005; Gold et al.,
2006; Becher et al., 2006). Whereas the expression of CXCL1,
CXCL2, CCL20, CXCL-12, GM-CSF, IL-6, MMP3, and MMP9
was induced in control mice, the induction of these inflammatory
genes was greatly reduced in NesCreAct1fl/ mice (Figure 7F).
These results suggest that the impact of CNS-restricted Act1
deficiency in the induction of EAEwas probably due to the defect
of IL-17-induced inflammatory gene expression in these mice.
Becauseastrocyteshavebeenshown tobe responsive to IL-17
and play a major role in the production of cytokines and chemo-
kines during EAE (Dong and Benveniste, 2001; Trajkovic et al.,
2001), we examined astrocytes from NesCreAct1fl/+ and
NesCreAct1fl/ mice. IL-17-mediated NF-kB activation (phos-
phorylation and degradation of IkB) was abolished in astrocytes
fromNesCreAct1fl/ compared to that in control cells (Figure 7G).
IL-17- and IL-17+TNF-induced inflammatory gene expression
was reduced in Act1-deficient astrocytes as compared to that
in controlmice (Figure 7H; Figure S4A). Becauseprevious studies
reported that astrocytes are also responsive to IFN-g (Croitoru-
Lamoury et al., 2003; Halonen et al., 2006), we examined the
gene expression profile of astrocytes in response to IL-17+TNF
and IFN-g+TNF. We found that distinct chemokines were
induced by IL-17+TNF and IFN-g+TNF in astrocytes. CXCL1,
CXCL2, and CCL20 were specifically induced by IL-17+TNF in
an Act1-dependent manner, whereas CXCL9, CXCL10, and
CXCL11were only inducedby IFN-g+TNF (but not by IL-17+TNF)
in both wild-type and Act1-deficient astrocytes (Figure 7H).
Taken together, these results implicate astrocytes as the prob-
able source, contributing to the different mechanisms utilized
by Th1 and Th17 cells to mediate EAE.
Neurons fromwild-type mice had very weak response to IL-17
stimulation and the synergistic effect between IL-17 with TNF
was not observed in these cells (Figure S4B). Because Act1 defi-
ciency in endothelial or myeloid cells did not have substantial
impact on EAE phenotype, it is important to determine whether
they are indeed unresponsive to IL-17, similar to what was
observed for neuron cells. We found that IL-17 stimulation alone
failed to induce inflammatory gene expression in microglial or
endothelial cells (Figures S4C and S4D). Although endothelial
cells and microglia were highly responsive to TNF, IL-17 had
modest effect only on some of the TNF-induced genes in
these cells that might be compensated by other inflammatory
cytokine signaling (such as TNF or IL-1 signaling) on these
cells during EAE. Taken together, these results suggest that
the reduction of IL-17 signaling in Act1-deficient astrocytes
probably contributes to EAE resistance in Act1-deficient and
NesCreAct1fl/ mice.
Figure 6. Macrophage- and Microglial-
Derived Act1 Are Dispensable for EAE
Development
(A) Real-time PCR for the Act1 expression in bone
marrow-derived macrophages and microglia
from the macrophage/microglia-specific Act1-
deficient (CD11bCreAct1fl/) and control
(CD11bCreAct1fl/+) mice.
(B) Immunoblot analysis for the Act1 expression in
bone marrow-derived macrophages from the
macrophage- and microglia-specific Act1-
deficient (CD11bCreAct1fl/) and control
(CD11bCreAct1fl/+) mice.
(C)Meanclinical scoreofEAE inCD11bCreAct1fl/
and CD11bCreAct1fl/+ mice induced by active
immunization with MOG 35-55 (n = 5/group).
(D) Mean clinical score of EAE in the
CD11bCreAct1fl/ and CD11bCreAct1fl/+ mice
induced by MOG-specific Th17 cells.
(E) Flow cytometry analysis of immune cell infiltra-
tion in the brains of MOG 35-55 immunized
CD11bCreAct1fl/ and CD11bCreAct1fl/+ mice
(n = 5, 7 days after disease onset).
Error bars, SEM; *p < 0.05.
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Here we have addressed how Act1, the key adaptor molecule of
IL-17-mediated signaling in different cellular compartments,
participates in the inflammatory process in the CNS, leading to
the pathogenesis of EAE. Importantly, we found that deletion
of Act1 in the neuroectoderm-derived cells (including astrocytes,
oligodendrocytes, and neurons), but not in endothelial cells or
macrophages and microglia, delayed the onset and reduced
the severity of Th17 cell-induced EAE. Furthermore, IL-17-medi-
ated production of cytokines and chemokines was impaired in
astrocytes from these CNS-restricted Act1-deficient mice,
consistent with reduced recruitment of inflammatory cells in
CNS of these mice and their resistance to EAE.
Previous studies have demonstrated the important role of acti-
vated CD4+ Th17 cells for the effector stage of EAE development
through the production of IL-17. Recent studies have shown that
IL-17-producing gd T cells were found at substantial frequency in
the brain of mice with EAE (Sutton et al., 2009; Wohler et al.,
2009). It has been proposed that IL-17-secreting gd T cells coop-
erate with CD4+ T cells in the development of EAE. We also de-
tected IL-17-producing gdT cells in the primed lymph node cells
and in the brain of mice with EAE. Regardless of the source of
IL-17, IL-17 antibody attenuates the induction of chemokines,
delays the onset of EAE, and reverses the progress of EAE
(Park et al., 2005; Weaver et al., 2005; Gold et al., 2006; Becher
et al., 2006). IL-17 or IL-17 receptor deficiency reduces the
disease severity of EAE (Gonzalez-Garcı´a et al., 2009; Komiyama
et al., 2006; Park et al., 2005; Harrington et al., 2005; Veldhoen
et al., 2006). Consistently, although activated wild-type and
Act1-deficient MOG 35-55-specific Th17 cells (IL-17-producing
T cells, activated in the presence of IL-23 in primary culture)
induced EAE in wild-type recipient mice, the onset and severity
of EAE were greatly reduced in Act1-deficient recipient mice,
demonstrating that Act1 is indeed required for the effector stageof EAE induced by Th17 cells. It is important to note that similar
onset and severity of EAE were induced in wild-type and Act1-
deficient recipient mice after adoptive transfer of wild-type acti-
vated MOG-specific Th1 cells (IFN-g-producing cells, activated
in the presence of IL-12 in the primary culture), indicating that
Act1 deficiency does not impact Th1 cell-mediated EAE. Taken
together, these results confirm the critical role of IL-17-
producing T cells in EAE development and pathogenesis and
demonstrate the essential role of IL-17-induced Act1-mediated
pathway in this disease process.
The important question is how IL-17-mediated signaling
contributes to the effector stage of Th17 cell-induced EAE. The
effector stage of EAE includes the recruitment and reactivation
of neuroantigen-reactive CD4+ T lymphocytes and subsequent
inflammatory response within CNS. After priming in lymph
nodes, antigen-specific Th17 cells traffic through the choroid
plexus into the subarachnoid space (Wave 1) where they are re-
activated (Reboldi et al., 2009; Ransohoff, 2009). As a conse-
quence of productive T cell-APC interactions, Th17 cell signa-
ture cytokines, including IL-17, are produced and impinge on
the adjacent CNS tissue. After activation of the parenchymal
vasculature by this cytokine flux, perivascular leukocyte infil-
trates accumulate (Wave 2), leading to the explosive inflamma-
tory cascade associated with the onset of EAE. Th17 cells had
been proposed to act either on glial cells (including astrocytes
and microglia) or directly on endothelial cells to promote BBB
disruption (Kebir et al., 2007; Das Sarma et al., 2009). We
demonstrated that Act1 deficiency in endothelial or myeloid cells
did not have a substantial impact on EAE phenotype. Instead,
the deletion of Act1 in neuroectoderm cells abolished the induc-
tion of EAE, indicating the essential role of this particular cellular
compartment in Th17 cell-mediated EAE.
Astrocytes are neuroectoderm cells whose direct contacts
with the glial limitans and the cerebral vasculature enables
them to couple inflammatory cytokine expression to invasionImmunity 32, 414–425, March 26, 2010 ª2010 Elsevier Inc. 421
Figure 7. Amelioration of EAE by Targeting Act1 in CNS-Resident Cells Derived from Neuroectodermal Cells
(A) Immunoblot analysis for the Act1 expression in the brains and astrocytes from CNS-restricted Act1-deficient (NesCreAct1fl/) and control mice
(NesCreAct1fl/+).
(B) Mean clinical score of EAE in NesCreAct1fl/ and NesCreAct1fl/+ mice induced by active immunization with MOG 35-55.
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Act1 in Central Nervous System Is Critical for EAEof theCNSby hematogenous leukocytes. IL-17 stimulation alone
induced inflammatory gene expression (CXCL1 and GM-CSF)
only in astrocytes but not in microglia or endothelial cells. Inflam-
matory cytokines, chemokines, and MMPs (including GM-CSF,
CXCL12, CCL20, and MMP9) were synergistically induced by
IL-17+TNF in astrocytes, but not in endothelial cells or microglia.
Thus, astrocytes might directly respond to IL-17 from Th17 cells
to produce cytokines and chemokines, contributing to Th17 cell-
mediated EAE. Based on our findings, we propose that IL-17-
induced Act1-mediated signaling cascades led to inflammatory
gene expression in astrocytes, which is critical for the conversion
of Wave 1 to Wave 2, contributing to Th17 cell-mediated patho-
genesis of EAE. However, it is important to note that Act1 is also
required other IL-17-related signaling, such as the IL-25 pathway
(Swaidani et al., 2009; Claudio et al., 2009). Although IL-25 was
shown to have an inhibitory impact on Th17 cell differentiation
and function in an EAE model (Kleinschek et al., 2007), we found
that astrocytes were not responsive to IL-25 stimulation (data not
shown). The role of Act1 in CNS-resident cells is probably
restricted to its signaling in the IL-17 pathway. Future studies
are required to carefully compare and contrast the phenotypes
of the CNS cell type-specific IL-17RC- and Act1-deficient mice.
We show that distinct chemokines were induced by
IL-17+TNF and IFN-g+TNF in astrocytes. Although CXCL1,
CXCL2, and CCL20 were specifically induced by IL-17+TNF in
an Act1-dependent manner, CXCL9, CXCL10, and CXCL11
were only induced by IFN-g+TNF but not by IL-17+TNF in both
wild-type and Act1-deficient astrocytes. Consistent with our
finding, a recent study showed that IFN-g-induced CXCL9, 10,
and 11 were preferentially expressed in the CNS of mice injected
with IL-12p70 (Th1 cell)-modulated T cells, whereas the neutro-
phil-attracting chemokines CXCL1 andCXCL2were upregulated
in the CNS of mice given IL-23 (Th17 cell)-modulated T cells
(Kroenke et al., 2008). Taken together, it is plausible that astro-
cytes receive signals from both Th1 and Th17 cells to produce




Act1-deficient mice in the C57BL/6J background were generated as
described (Qian et al., 2004). B6.Cg-Tg(Nes-Cre)1Kln/J (NesCre transgenic),
C57BL/6J, and B6.PL-Thy1a/CyJ (Thy1.1 B6) mice were purchased from
Jackson laboratory. CD11bCre transgenic mice were provided by G. Kollias
(Biomedical Sciences Research Centre ‘‘Alexander Fleming’’) (Boille´e et al.,
2006). TIE2eCre transgenic mice were a gift of X.-Y. Fu (National University(C) Luxol fast blue, anti-CD11b, and anti-CD4 staining of spinal cords of NesCreAc
after disease onset). Data are representative of three independent experiments.
(D) Mean clinical score of Th1 cell-induced EAE (top) and flow cytometry ana
NesCreAct1fl/+ mice (n = 5, 15 days after T cell transfer).
(E) Mean clinical score of Th17 cell-induced EAE (top) and flow cytometry ana
NesCreAct1fl/+ mice (n = 5, 15 days after T cell transfer).
(F) Real-time PCR analysis of relative expression of inflammatory genes as indica
MOG-specific Th17 cells (n = 3, 15 days after T cell transfer) compared to the co
(G) Primary astrocytes from NesCreAct1fl/ and NesCreAct1fl/+ mice were treated
indicated antibodies.
(H) Differential regulation of chemokines by IL-17 and IFN-g in astrocytes. Astroc
IL-17, 10 ng/ml TNF-a, 10 ng/ml IFN-g, medium alone, IL-17+TNF-a, and TNF-a+
genes as indicated.
The data are presented as mean ± SEM from three independent experiments (*pof Singapore) (Kano et al., 2003). All mice used in the experiment were housed
under specific-pathogen-free conditions. Experimental protocols were
approved by the Institutional Animal Care and Use Committee of Cleveland
Clinic.
Induction and Assessment of EAE
Active EAE was induced and assessed as previously described (Qian et al.,
2007). For passive EAE, Act1-deficient or wild-type control mice were injected
with 3.0 3 107 polarized MOG 35-55-specific Th1 or Th17 cells/mouse 4 hr
after 500 Rad sublethal irradiation. To prepare MOG-specific polarized T cell
populations, drain lymph node cells were prepared from mice immunized as
described above at day 10 postimmunization. Cells were cultured for 5 days
with MOG 35-55 at a concentration of 25 mg/ml under Th1 cell (20 ng/ml
rmIL-12 [R&D], 2 mg/ml aIL-23p19 [eBioscience]) polarizing conditions or
Th17 cell (20 ng/ml rmIL-23 [R&D]) polarizing condition.
Isolation and Analysis of CNS Inflammatory Cells
Brains were homogenized in ice-cold tissue grinders and filtered through
a 100 mm cell strainer, and the cells were collected by centrifugation at
400 3 g for 5 min at 4C. Cells were resuspended in 10 ml of 30% Percoll
(Amersham Bioscience) and centrifuge onto a 70% Percoll cushion in 15 ml
tubes at 800 3 g for 30 min. Cells at the 30%–70% interface were collected
and were subjected to flow cytometry. Fluorescence-conjugated CD4, CD8,
CD11b, CD45, Ly6G, IL-17, IL-4, and IFN-g monoclonal antibodies and iso-
type controls were purchased from BD Biosciences. F4/80 was obtained
from Serotech.
Histological Analysis
For paraffin-embedded tissue, spinal cord removed from PBS-perfused mice
was fixed in 10% formalin. Sections were stained with either hematoxylin and
eosin (H&E) or luxol fast blue (LFB) to evaluate inflammation and demyelin-
ation, respectively. For frozen sections, spinal cords were embedded in OCT
(Tissue-Tek) and snap frozen in liquid nitrogen. Sections (10 mm) were incu-
bated with anti-CD4, anti-CD11b, anti-Thy1.1 (BD Biosciences), anti-laminin
(Sigma). Antigens were visualized after incubation with HRP- or fluores-
cence-conjugated secondary antibodies (Molecular Probe).
Primary Neuronal Cell Cultures
Mixed glial culture was prepared from 1- to 2-day-old mice. In brief, brains
freed of meninges were dissociated with 1 ml pipettes. Debris was removed
by filtration with a 40 mm cell strainer (Falcon). Cells were cultured in DMEM
plus 10% FBS supplemented with 50 mg/ml penicillin and 50 mg/ml strepto-
mycin. For isolation ofmicroglia, confluentmonolayerswere vigorously shaken
between day 12 and 14, and the floating cells were collected and replated on
6-well plates and cultured for one more hour. Microglial cells attached to the
plates and were collected by trypsin digestion. For gene expression experi-
ments, microglial cells were further sorted by anti-CD11b microbeads and
purity was >95%. Astrocytes stained with anti- glial fibrillary acidic protein
(GFAP) (Santa Cruz) and purity was >90%. Neurons were prepared from the
pups at E15. Brains were dissociated with 1 ml pipettes and the debris
removedwith a 70 mmcell strainer (Falcon). Cells were cultured in Neuronbasal
media (Invitrogen) plus B-27 (Invitrogen) and 50 mg/ml penicillin and 50 mg/mlt1fl/ andNesCreAct1fl/+mice after immunization withMOG35-55 (n = 5, 7 days
lysis of immune cell infiltration in the brains (bottom) of NesCreAct1fl/ and
lysis of immune cell infiltration in the brains (bottom) of NesCreAct1fl/ and
ted in spinal cords of NesCreAct1fl/ and NesCreAct1fl/+ mice transferred with
ntrol samples from naive mice.
with 50 ng/ml IL-17 for the indicated times and analyzed by immunoblot with
ytes from NesCreAct1fl/ and NesCreAct1fl/+ mice were treated with 50 ng/ml
IFN-g for 16 hr, followed by real-time PCR for the expression of inflammatory
< 0.05). See also Figures S3 and S4.
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for neurons, anti-MAP2 from Abcam).
ELISA
IL-17 and IFN-g level were assayed by IL-17- or IFN-g ELISA kit (R&D systems)
according to the manufacturer’s instruction.
Real-Time PCR
Total RNA was extracted from spinal cord and cultured astrocytes with TRIzol
(Invitrogen) according to the manufacturer’s instructions. All gene expression
results are expressed as arbitrary units relative to expression of the gene en-
coding b-actin. Fold induction of gene expression in spinal cord after EAE
induction was determined by dividing the relative abundance of experimental
samples by the mean relative abundance of control samples from naive mice.
Primer sequences are available in Supplemental Experimental Procedures.
Proliferation and Apoptosis Assay
Cell division was detected with the Brdu In Situ detection kit (BD Biosciences)
according to manufacturer’s instructions. The percentage of Brdu-positive
cells in total CD4+ cells was averaged of four spinal cord regions after double
staining by anti-Brdu and anti-CD4. Ki67 antibody (Dako) was also used for
proliferation analysis by immunohistochemical staining. The frequency of
Ki67+ cells in total Thy1.1+ cells in the spinal cord represents an average of
four spinal cord regions.
Statistics
The p values of clinical scores were determined by one-way multiple-range
analysis of variance (ANOVA) for multiple comparisons. Other p values were
determined by Student’s t tests. Unless otherwise specified, all results are
shown as mean and the standard error of the mean (mean ± SEM). A p value
of < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at doi:10.1016/
j.immuni.2010.03.004.
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